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Sir,
In the first reported study to specifically define and address the
issue of women presenting with stage IV breast cancer, we have
recently evaluated the incidence and clinical course of initially
metastatic breast cancer (IMBC) in a series of 1350 patients
diagnosed and treated between 1992 and 1998 at our Institution
(Jimeno et al, 2004). In this cohort, 8.9% of the patients presented
with IMBC, a figure that is slightly greater than the reported
incidence for stage IV breast cancer in the European Union (Sant,
2001), and higher than that reported in the analysis subject of this
letter (Remak and Brazil, 2004). The fact that our data arises from
a third-level Institution as opposed to population-based cancer
registries, and that we classified as IMBC those cases in which
metastases were detected in the first 3 months, may contribute to
these differences.
It is very relevant for a cost analysis that we observed a median
overall survival for the IMBC group of 25.1 months. These are to
our knowledge the only published survival data in this subset of
patients. The difference between this figure, and that used by
Rema ´k and Brazil (18 months, derived from Royal Marsden
Hospital data), may therefore increase 40% the estimated cost of
managing stage IV breast cancer. Thus, even if we consider that the
true incidence of IMBC is 5%, the authors may have under-
estimated the real financial burden of IMBC management (d17500
instead of d12500).
Adding to the survival-related underestimation, Rema ´k
and Brazil calculated costs by assuming that 17 and 5% of patients
received taxanes and trastuzumab, two of the most
costly medications in our present therapeutic armamentarium.
In a recent report assessing the patterns of treatment for metastatic
cancer patients in Italy, taxanes were used initially in 46%
of the patients (Cazzaniga et al, 2004). Despite ongoing
controversies regarding which and when, the taxanes are
being increasingly incorporated to the first-line setting, especially
in anthracycline-resistant patients (Bernard-Marty et al,
2003), typically with four to six cycles. Regarding trastuzumab,
there are not comprehensive reports indicating the proportion
of patients who ultimately receive the antibody at some
point during the course of their disease, but considering that
approximately 20% of patients are HER2 positive, and that there
is an increasing tendency to continue trastuzumab therapy despite
disease progression (Gelmon et al, 2004), the reported estimates
of 5% appear unrealistic. These figures would impact significantly
what the authors considered the active phase of stage IV
breast cancer. Assuming just four cycles of taxane-containing
chemotherapy in 30% of patients with metastatic breast
cancer would increase the tentative lifetime cost per patient in
d3200.
Therefore, the cost of treating women presenting with stage IV
breast cancer can be estimated to be at least d20700. Increasing
costs of advanced breast cancer should be put in context with
overall population results end points, such as survival gains, which
unfortunately are not usually reported separately for stage IV
breast cancer.
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